###### Strengths and limitations of this study

-   To our knowledge, this will be the first systematic review and meta-analysis aiming to estimate the incidence of complications after renal biopsies in low-income to middle-income countries.

-   We aim to look at the distribution of biopsy complications according to income group, providing comparisons that may be useful in designing strategies to improve safety of renal biopsies in this region.

-   There could be heterogeneity from studies from different regions, which may affect pooled estimates.

-   The limited number of patients having renal biopsies in some countries may affect true incident rates.

Introduction {#s1}
============

Kidney biopsy is an essential tool for guiding clinicians towards the diagnosis of unexplained renal disease, guide treatment of patients or assist with determination of prognosis of renal disease.[@R1] Since its first introduction in 1944 and later in 1951 by Iversen and Brun, the procedure has provided clinicians with valuable information about kidney diseases and their management despite high rates of reported biopsy complications.[@R2] Improvements of the technique and recent introduction of the spring-loaded biopsy gun have reduced some of these complications.[@R2]

The reported occurrence of complications following a kidney biopsy tend to vary from one region to another. A study from China, a middle-income country, reported incidence of severe bleeding to be 0.39% out of 3577 native kidney biopsies.[@R3] However, much higher rates have been reported in other parts of the world.[@R4] In Morocco, 12.3% of patients who had undergone a percutaneous native kidney biopsy had gross haematuria and 0.8% required nephrectomy after biopsy.[@R4] On the other hand, a systematic review with studies mainly from high-income countries found that only 0.9% of 9474 renal biopsies required red blood cell transfusion.[@R7] However, the review only included studies if renal biopsy was performed by real-time ultrasound using automatic biopsy needles.[@R7] Due to lack of such equipment in developing countries, no low-income to middle-income country (LMIC) was included in that study, making their results difficult to generalise globally.

The use of automated spring-loaded biopsy devices under real-time ultrasound guidance for performance of renal biopsy is becoming increasingly common in many centres.[@R2] However, there are studies that have shown that the spring-driven needles may yield similar complication rates when compared with hand-driven needles.[@R8] Similarly, while minor complications have been shown to be increased with use of free hand rather than real-time ultrasound, the incidence of major complications has been shown to be similar in both techniques.[@R9] This is further supported by studies reporting no difference in diagnostic yield or occurrence of complications between ultrasound marked or blind biopsies.[@R8] Other factors that may influence the rates of complications are the size of needle used as some studies show that large-calibre needles such as the 14G needle may result in higher bleeding complications when compared with smaller needles.[@R7] Other studies have, however, found no difference in complication rates based on size of needle used for the procedure.[@R2] Operator experience and training may also affect the reported incidence of renal biopsy complications.[@R10] Finally, despite the increasing number of kidney biopsies being performed by radiologists, there is no evidence that they are safer than those performed by nephrologists.[@R11]

This systematic review aims to summarise available data on the incidence of reported complications in patients undergoing percutaneous renal biopsy in LMICs. It is anticipated this will provide essential data to aid the global strategy in curbing kidney disease in LMIC.[@R13] This is important as it will provide information regarding the safety of performing renal biopsies, especially in LMICs where glomerular diseases are common causes of chronic kidney disease and remain largely undiagnosed.[@R14]

Research objectives {#s2}
===================

This review aims to report on the incidence of major complications associated with performance of renal biopsies in LMIC.

Review question {#s3}
===============

What is the incidence of major complications after renal biopsy in adults undergoing percutaneous renal biopsy in LMIC?

We will define major complications as any complication requiring an intervention, for example blood transfusion, radiographic or surgical invasive procedure, acute renal obstruction, extended hospitalisation, septicaemia or death. Minor complications will be those that are expected to resolve spontaneously, for example, pain after biopsy or mild haematuria resolving spontaneously without the need for blood transfusion or other interventions.

Methods {#s4}
=======

The development of this protocol was done using the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) framework.[@R15]

Criteria for considering studies for the review {#s4a}
-----------------------------------------------

### Inclusion criteria {#s4a1}

1.  Studies done in LMICs reporting on complications after percutaneous native renal biopsies from 1 January 1980 to 30 December 2017 will be included. We will focus on the period after 1980 given that the techniques of renal biopsies changed substantially after 1980 with increased use of ultrasound and automatic needles.[@R2]

2.  We will consider relevant cohort, cross-sectional or case--control studies from LMIC.

3.  Studies with patients 18 years and above.

### Exclusion criteria {#s4a2}

1.  Studies reporting biopsies of tumours or kidney masses.

2.  Studies with fewer than 30 patients.

3.  Editorials and review articles.

4.  Studies from high-income countries.

5.  Studies reporting on kidney transplant biopsies only.

6.  Studies with duplicate publications. In such cases, we will consider only the most up-to-date and comprehensive publication.

7.  Studies with inaccessible data even after request from the authors.

Search strategy for identifying relevant studies {#s4b}
------------------------------------------------

1.  Bibliographic database searches: We will search PubMed, Excerpta Medica Database (Embase), Cochrane and African Journals Online databases for relevant abstracts. The search will be performed from 1 January 1980 to 30 December 2017 with no language restriction ([table 1](#T1){ref-type="table"}). Conference abstracts and grey literature studies will also be considered. Dissertations and theses will be searched from ProQuest Dissertations, Theses Online, Networked Digital Library of Theses and Dissertations and the Open Access.

2.  All relevant abstracts from above sources will be scrutinised and full papers downloaded from the databases or journal websites. The references of these papers will be checked for potentially eligible studies, which will be assessed for eligibility.

###### 

Search strategy for PubMed

  ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#1   Kidney biopsy OR Renal biopsy
  \#2   Complications OR Adverse events OR Adverse effects OR haematoma OR Hematoma OR hemorrhage OR haemorrhage OR bleeding OR blood transfusion OR Red blood cell transfusion OR Erythrocyte transfusion OR red cell transfusion OR cauterisation OR embolisation OR embolization OR Bladder Obstruction OR Arteriovenous fistula OR Arteriovenous aneurysm OR pseudo aneurysm OR Infection OR Angiography OR Needle OR Fine needle OR Ultrasound guided OR nephrectomy OR death
  \#3   ((Afghanistan \[tiab\] OR Albania \[tiab\] OR Algeria \[tiab\] OR American Samoa \[tiab\] OR Angola \[tiab\] OR Argentina \[tiab\] OR Armenia \[tiab\] OR Azerbaijan \[tiab\] OR Bangladesh \[tiab\] OR Belarus \[tiab\] OR Belize \[tiab\] OR Benin \[tiab\] OR Bhutan \[tiab\] OR Bolivia \[tiab\] OR Bosnia and Herzegovina \[tiab\] OR Botswana \[tiab\] OR Brazil \[tiab\] OR Bulgaria \[tiab\] OR Burkina Faso \[tiab\] OR Burundi \[tiab\] OR Cabo Verde \[tiab\] OR Cambodia \[tiab\] OR Cameroon \[tiab\] OR Central African Republic \[tiab\] OR Chad \[tiab\] OR China \[tiab\] OR Colombia \[tiab\] OR Comoros \[tiab\] OR Congo, Dem. Rep. \[tiab\] OR Congo, Rep. \[tiab\] OR Costa Rica \[tiab\] OR Ivory Coast \[tiab\] OR Cote d'Ivoire \[tiab\] OR Cuba \[tiab\] OR Djibouti \[tiab\] OR Dominica \[tiab\] OR Dominican Republic \[tiab\] OR Ecuador \[tiab\] OR Egypt \[tiab\] OR El Salvador \[tiab\] OR Equatorial Guinea \[tiab\] OR Eritrea \[tiab\] OR Ethiopia \[tiab\] OR Fiji \[tiab\] OR Gabon \[tiab\] OR Gambia \[tiab\] OR Georgia \[tiab\] OR Ghana \[tiab\] OR Grenada \[tiab\] OR Guatemala \[tiab\] OR Guinea \[tiab\] OR Guinea-Bissau \[tiab\] OR Guyana \[tiab\]) OR Haiti \[tiab\] OR Honduras \[tiab\] OR India \[tiab\] OR Indonesia \[tiab\] OR Iran, Islamic Rep. \[tiab\] OR Iraq \[tiab\] OR Jamaica \[tiab\] OR Jordan \[tiab\] OR Kazakhstan \[tiab\] OR Kenya \[tiab\] OR Kiribati \[tiab\] OR Korea, Dem. People's Rep. \[tiab\] OR Kosovo \[tiab\] OR Kyrgyz Republic \[tiab\] OR Lao PDR \[tiab\] OR Lebanon \[tiab\] OR Lesotho \[tiab\] OR Liberia \[tiab\] OR Libya \[tiab\] OR Macedonia \[tiab\] OR Madagascar \[tiab\] OR Malawi \[tiab\] OR Malaysia \[tiab\] OR Maldives \[tiab\] OR Mali \[tiab\] OR Marshall Islands \[tiab\] OR Mauritania \[tiab\] OR Mauritius \[tiab\] OR Mexico \[tiab\] OR Micronesia \[tiab\] OR Moldova \[tiab\] OR Mongolia \[tiab\] OR Montenegro \[tiab\] OR Morocco \[tiab\] OR Mozambique \[tiab\] OR Myanmar \[tiab\] OR Namibia \[tiab\] OR Nepal \[tiab\] OR Nicaragua \[tiab\] OR Niger \[tiab\] OR Nigeria \[tiab\] OR Pakistan \[tiab\] OR Palau \[tiab\] OR Panama \[tiab\] OR Papua New Guinea \[tiab\] OR Paraguay \[tiab\] OR Peru \[tiab\] OR Philippines \[tiab\] OR Romania \[tiab\] OR Russian Federation \[tiab\] OR Rwanda \[tiab\] OR Samoa \[tiab\] OR São Tomé and Princip \[tiab\] OR Senegal \[tiab\] OR Serbia \[tiab\] OR Sierra Leone \[tiab\] OR Solomon Islands \[tiab\] OR Somalia \[tiab\] OR South Africa \[tiab\] OR South Sudan \[tiab\] OR Sri Lanka \[tiab\] OR St. Lucia \[tiab\] OR St. Vincent and the Grenadines \[tiab\] OR Sudan \[tiab\] OR Suriname \[tiab\] OR Swaziland \[tiab\] OR Syrian Arab Republic \[tiab\] OR Tajikistan \[tiab\] OR Tanzania \[tiab\] OR Thailand \[tiab\] OR Timor-Leste \[tiab\] OR Togo \[tiab\] OR Tonga \[tiab\] OR Tunisia \[tiab\] OR Turkey \[tiab\] OR Turkmenistan \[tiab\] OR Tuvalu \[tiab\] OR Uganda \[tiab\] OR Ukraine \[tiab\] OR Uzbekistan \[tiab\] OR Vanuatu \[tiab\] OR Venezuela \[tiab\] OR Vietnam \[tiab\] OR West Bank and Gaza \[tiab\] OR Yemen, Rep. \[tiab\] OR Zambia \[tiab\] OR Zimbabwe \[tiab\]))
  \#4   \#1+ \#2 + \#3
  \#5   Limits \#4: Humans, 1980/01/01 to 2017/12/30
  ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Selection of studies deemed relevant for inclusion in the review {#s4b1}

Two reviewers (SK and MWM) will independently search the databases for relevant abstracts using agreed study inclusion and exclusion criteria. The full texts of these abstracts will again be independently assessed by these reviewers for eligibility. Any differences will be resolved by a third reviewer (IGO).

Assessment of methodological quality and reporting of data {#s4c}
----------------------------------------------------------

For risk of bias assessment, we will adapt and use a tool developed by Hoy *et al* to assess the methodological quality of included studies.[@R17] This will be presented in a table format.

Data extraction and management {#s4d}
------------------------------

The data will be extracted onto a predeveloped data capture sheet. We will collect the following information: country of biopsy (in cases of multinational studies, information from individual countries will be presented separately where possible), World Bank Income Group, author, year of publication, study design, sample size, mean age, gender, the reported incidence of various postrenal biopsy complications, method of biopsy (free hand, ultrasound guided or ultrasound marking), needle size, type of needle used for the biopsy (automatic, manual), indication of biopsy, factors associated with major bleeding, for example, elevated blood pressure, platelet count and coagulation parameters, and operator (nephrologist, radiologist, trainee).

Statistical analysis {#s4e}
--------------------

A meta-analysis will be used to summarise incidence data. We will pool the study-specific estimates using a random-effects meta-analysis model (DerSimonian-Laird) to obtain an overall summary estimate of the incidence of complications across studies.[@R18] The incidence rates follow a Poisson distribution. Therefore, the square-root transformation will be applied to stabilise the variance of the incidence rates prior to meta-analyses, and the estimates back-transformed for reporting. Heterogeneity will be assessed using the χ² test on Cochrane's Q statistic[@R19] and quantified by calculating the I² (with values of 25%, 50% and 75% representing low, medium and high heterogeneity, respectively).[@R20] Subgroup analysis will be performed using the Q-test based on ANOVA. We will assess the presence of publication bias using funnel plots and Egger's test.[@R21] We will also assess inter-rater agreement for study inclusion and data extraction using Cohen's kappa (κ) coefficient.[@R22] A P value \<0.05 will be considered indicative of statistically significant difference between subgroups. All analyses will be performed using Stata V.15 (StataCorp, College Station, Texas, USA).

Analysis of subgroups or subsets {#s4f}
--------------------------------

The following subgroups will be considered for analysis:Gender: male versus female.Geographic location, income group (low income versus middle income) as per 2017 World Bank country list.Needle size (14G vs 16G vs 18G).Biopsy technique (blind vs real time vs ultrasound assisted).Needle type (spring loaded versus manual).

Reporting of results and presentation {#s4g}
-------------------------------------

A PRISMA flow diagram will be used to present the study selection process ([figure 1](#F1){ref-type="fig"}). We will use the PRISMA Guidelines to present our data.[@R23] Quantitative data will be presented in tables and forest plots if applicable. The prevalent complication rates in various LMIC regions will be presented and comparisons made.

![Flow diagram for study selection.](bmjopen-2017-020891f01){#F1}

Conclusion {#s5}
==========

Kidney biopsies are essential to help manage kidney disease. Unfortunately, access to this resource is limited in poorly resourced countries. It is important to gather accurate data on renal biopsies from LMIC to aid policy-making and improvements to be made where necessary. We hope this review will help to highlight challenges faced in performing renal biopsies in this region.
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======================
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